The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein - PubMed (original) (raw)
- PMID: 1159076
- PMCID: PMC301910
- DOI: 10.1172/JCI108132
The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein
G J Roth et al. J Clin Invest. 1975 Sep.
Abstract
Aspirin (acetylsalicylic acid) inhibits platelet prostaglandin synthesis and the ADP- and collagen-induced platelet release reaction. The mechanism of the inhibitory effect is unknown but may involve protein acetylation, since aspirin acetylates a variety of substrates, including platelet protein. We have examined the relationship between protein acetylation and aspirin's physiologic effect on platelets. Suspensions of washed human platelets were incubated at 37 degrees C with (3H)aspirin, and incorporation of radioactivity into protein was analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Exposure to (acetyl-3H)aspirin but not (aromatic ring-3H)aspirin resulted in radioactive labeling of three platelet proteins, suggesting that the drug acetylates these three proteins. The acetylation of two of the proteins (located in the supernatant fraction) was not saturable, implying that these reactions may not be physiologically significant. Acetylation of the third protein, approximate mol wt 85,000 (located in the particulate fraction), saturated at an aspirin concentration of 30 muM and was complete within 20 min. Platelets prepared from aspirin-treated donors did not incorporate any (acetyl-3H)aspirin radioactivity into the particulate protein for 2 days after drug treatment and did not show full pretreatment uptake of radioactivity for 12 days thereafter. The course of increasing incorporation of (acetyl-3H)aspirin radioactivity parralleled that of platelet turnover. Therefore, in addition to its saturability, acetylation of the particulate fraction protein by aspirin was permanent. In two respects, the inhibition of platelet function by aspirin correlates well with the aspirin-mediated acetylation of the particulate fraction protein. Both persist for the life-span of the aspirin-treated platelet, and both occur at a similar saturating aspirin concentration. The evidence suggests that the physiologic effect of aspirin on human platelets is produced by acetylation of a single protein located in the particulate fraction. The acetylated protein may be related to cyclo-oxygenase, the prostaglandin G2 biosynthetic enzyme.
Similar articles
- Inhibition of platelet prostaglandin synthetase by oral aspirin.
Burch JW, Stanford N, Majerus PW. Burch JW, et al. J Clin Invest. 1978 Feb;61(2):314-9. doi: 10.1172/JCI108941. J Clin Invest. 1978. PMID: 413839 Free PMC article. - Gel-filtered human platelets. Ultrastructure, function, and role of proteins in inhibition of aggregation by aspirin.
Fine KM, Ashbrook PC, Brigden LP, Maldonado JE, Didishelm P. Fine KM, et al. Am J Pathol. 1976 Jul;84(1):11-24. Am J Pathol. 1976. PMID: 59550 Free PMC article. - Aspirin acetylates nitric oxide synthase type 3 in platelets thereby increasing its activity.
O'Kane P, Xie L, Liu Z, Queen L, Jackson G, Ji Y, Ferro A. O'Kane P, et al. Cardiovasc Res. 2009 Jul 1;83(1):123-30. doi: 10.1093/cvr/cvp120. Epub 2009 Apr 17. Cardiovasc Res. 2009. PMID: 19377066 - Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back.
Patrono C. Patrono C. Trends Pharmacol Sci. 1989 Nov;10(11):453-8. doi: 10.1016/S0165-6147(89)80010-0. Trends Pharmacol Sci. 1989. PMID: 2514478 Review. - Are Platelets the Primary Target of Aspirin's Remarkable Anticancer Activity?
Lichtenberger LM, Vijayan KV. Lichtenberger LM, et al. Cancer Res. 2019 Aug 1;79(15):3820-3823. doi: 10.1158/0008-5472.CAN-19-0762. Epub 2019 Jul 12. Cancer Res. 2019. PMID: 31300475 Free PMC article. Review.
Cited by
- Perioperative Management of Antiplatelet Therapy in Ophthalmic Surgery.
Idrees S, Sridhar J, Kuriyan AE. Idrees S, et al. Int Ophthalmol Clin. 2020 Summer;60(3):17-30. doi: 10.1097/IIO.0000000000000317. Int Ophthalmol Clin. 2020. PMID: 32576720 Free PMC article. - Differential effect of aspirin on thromboxane and prostaglandin biosynthesis in man.
Ritter JM, Cockcroft JR, Doktor HS, Beacham J, Barrow SE. Ritter JM, et al. Br J Clin Pharmacol. 1989 Nov;28(5):573-9. doi: 10.1111/j.1365-2125.1989.tb03544.x. Br J Clin Pharmacol. 1989. PMID: 2590611 Free PMC article. Clinical Trial. - Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachidonate cyclooxygenase and antiinflammatory activity.
Higgs GA, Salmon JA, Henderson B, Vane JR. Higgs GA, et al. Proc Natl Acad Sci U S A. 1987 Mar;84(5):1417-20. doi: 10.1073/pnas.84.5.1417. Proc Natl Acad Sci U S A. 1987. PMID: 3103135 Free PMC article. - Aspirin all round?
Orme M. Orme M. Br Med J (Clin Res Ed). 1988 Jan 30;296(6618):307-8. doi: 10.1136/bmj.296.6618.307. Br Med J (Clin Res Ed). 1988. PMID: 3125876 Free PMC article. No abstract available. - Inhibition of platelet prostaglandin synthetase by oral aspirin.
Burch JW, Stanford N, Majerus PW. Burch JW, et al. J Clin Invest. 1978 Feb;61(2):314-9. doi: 10.1172/JCI108941. J Clin Invest. 1978. PMID: 413839 Free PMC article.
References
- J Pharmacol Exp Ther. 1971 Nov;179(2):410-8 - PubMed
- J Biol Chem. 1974 Apr 25;249(8):2646-51 - PubMed
- Proc Soc Exp Biol Med. 1970 Feb;133(2):632-6 - PubMed
- J Biol Chem. 1969 Aug 25;244(16):4406-12 - PubMed
- J Clin Invest. 1969 Mar;48(3):536-42 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources